Warkentin Theodore E, Makris Michael, Jay Richard M, Kelton John G
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Am J Med. 2008 Jul;121(7):632-6. doi: 10.1016/j.amjmed.2008.03.012.
Antibodies against the "self" protein, platelet factor 4 (PF4), bound to heparin-the cause of immune heparin-induced thrombocytopenia-are believed invariably to be triggered by preceding heparin therapy. We describe a novel syndrome, spontaneous heparin-induced thrombocytopenia, in which clinical and serologic features characteristic of this adverse drug reaction develop in patients despite the absence of preceding heparin therapy.
Three patients met the study criteria (clinical and serologic features of heparin-induced thrombocytopenia without preceding heparin exposure), of whom 2 patients were identified among 225 patients (0.89%, 95% confidence interval, 0.11%-3.17%) with serologically confirmed heparin-induced thrombocytopenia recognized during an 18-year period at 1 hospital. The platelet serotonin-release assay was used to detect heparin-dependent immunoglobulin G-induced platelet activation, and 2 enzyme immunoassays were used to detect antibodies against PF4/heparin.
Two patients presented with thrombocytopenia and multiple arterial thrombosis, and 1 patient presented with anaphylactoid reactions after 2 subcutaneous injections of low-molecular-weight heparin. All 3 patients had high levels of platelet-activating anti-PF4/heparin antibodies of immunoglobulin G class at presentation despite the absence of previous heparin exposure. However, each patient did have a preceding infectious or inflammatory event; 1 patient had concomitant antiphospholipid antibodies.
Circumstances other than heparin use can trigger a spontaneous disorder that closely mimics heparin-induced thrombocytopenia, further supporting the autoimmune nature of this adverse drug reaction.
与肝素结合的针对“自身”蛋白血小板因子4(PF4)的抗体——免疫性肝素诱导的血小板减少症的病因——被认为总是由先前的肝素治疗引发。我们描述了一种新型综合征,即自发性肝素诱导的血小板减少症,在这种综合征中,尽管没有先前的肝素治疗,但患者仍出现了这种药物不良反应的临床和血清学特征。
三名患者符合研究标准(有肝素诱导的血小板减少症的临床和血清学特征但无先前肝素暴露史),其中两名患者是在一家医院18年期间血清学确诊的225例肝素诱导的血小板减少症患者中识别出来的(0.89%,95%置信区间,0.11% - 3.17%)。采用血小板5-羟色胺释放试验检测肝素依赖性免疫球蛋白G诱导的血小板活化,并使用两种酶免疫测定法检测抗PF4/肝素抗体。
两名患者出现血小板减少症和多发性动脉血栓形成,一名患者在皮下注射两次低分子量肝素后出现类过敏反应。尽管没有先前的肝素暴露史,但所有三名患者在就诊时均有高水平的免疫球蛋白G类血小板活化抗PF4/肝素抗体。然而,每位患者确实有先前的感染或炎症事件;一名患者伴有抗磷脂抗体。
除使用肝素外的其他情况可引发一种与肝素诱导的血小板减少症极为相似的自发性疾病,这进一步支持了这种药物不良反应的自身免疫性质。